After AstraZeneca (AZN) presented data at the ObesityWeek conference, Deutsche Bank said the company’s oral small molecule GLP1 drug – AZD5004 – looks like it trails Eli Lilly’s (LLY) oral small molecule orforglipron’s profile and will be three years later to market. Looking at the body of data for weight loss, safety/tolerability and half-life, the firm reiterates its view that “5004’s differentiation (if any) looks too little and too late vs Orforg,” adds the analyst, who keeps a Buy rating and $1,015 price target on Eli Lilly shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- AstraZeneca says experimental obesity pill ‘competitive,’ Bloomberg reports
- Eli Lilly price target lowered to $1,015 from $1,025 at Deutsche Bank
- 3 Best Stocks to Buy Now, 11/4/2024, According to Top Analysts
- Viking Therapeutics surges after presenting ‘promising’ obesity drug data
- Eli Lilly earnings selloff brings buying opportunity, says JPMorgan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
